Health Care & Life Sciences » Pharmaceuticals | Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
179.45 M
Public Float
149.32 M
Synergy Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.65
Market Cap
$414.14 M
Shares Outstanding
247.99 M
Public Float
247.16 M

Profile

Address
420 Lexington Avenue
New York New York 10170
United States
Employees -
Website http://www.synergypharma.com
Updated 09/14/2018
Synergy Pharmaceuticals, Inc. engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The company was founded by Kunwar Shailubhai on November 15, 2005 and is headquartered in New York, NY.

Financials

View All
Created with Highcharts 5.0.14Synergy Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.62 12462 12495 70895 708117 500117 500198 607198 607224 338224 33820132014201520162017050k100k150k200k250k
Created with Highcharts 5.0.14Synergy Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.0000000016 82016 8202013201420152016201705k10k15k20k

Gary S. Jacob
Executive Chairman
Troy Hamilton
Chief Executive Officer & Director